This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Conquering a severe complication of celiac disease

May 3rd, 2010

One severe complication of celiac disease is enteropathy-associated T cell lymphoma, a high-grade invasive lymphoma with a very poor prognosis. Previous research has suggested that chronic exposure of immune cells in the walls of the small intestine, which are known as intraepithelial lymphocytes, to potent anti-death signals initiated by the soluble factor IL-15 contributes to the development of enteropathy-associated T cell lymphoma. A team of researchers, at INSERM U989, Université René Descartes, France, has now identified the survival signals delivered by IL-15 to freshly isolated human intraepithelial lymphocytes and to intraepithelial lymphocyte cell lines derived from patients with type II refractory celiac disease — a clinical state considered an intermediary step between celiac disease and enteropathy-associated T cell lymphoma. Importantly, treatment with an antibody directed at IL-15 caused intraepithelial lymphocytes to die and wiped out their accumulation in mice overexpressing human IL-15 in the lining of their gut. The team, led by Nadine Cerf-Bensussan and Bertrand Meresse, therefore suggests that IL-15 and its downstream survival signals might provide new targets for the treatment of type II refractory celiac disease.

More information:
View this article at: www.jci.org/articles/view/4134 … e1dc4f9eec5f2e932a64

Provided by Journal of Clinical Investigation

Citation: Conquering a severe complication of celiac disease (2010, May 3) retrieved 19 August 2026 from https://sciencex.com/wire-news/34363557/conquering-a-severe-complication-of-celiac-disease.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.